Surgical Oncology
Volume 19, Issue 1 , Pages e33-e46 , March 2010

An overview of coagulation disorders in cancer patients

  • Slavica Kvolik

      Affiliations

    • Department of Anesthesiology and ICU, University Hospital Osijek, J. Huttlera 4, 31000 Osijek, Croatia
    • Medical School Osijek, University J.J. Strossmayer, J. Huttlera 4, 31000 Osijek, Croatia
    • Corresponding Author InformationCorresponding author at: Department of Anesthesiology and ICU, University Hospital Osijek, J. Huttlera 4, 31000 Osijek, Croatia. Tel.: +385 31 511528; fax: +385 31 512222.
    • ,
  • Marko Jukic

      Affiliations

    • Clinical Hospital Centre, Split, Croatia
    • ,
  • Marko Matijevic

      Affiliations

    • Department of Maxillofacial Surgery, University Hospital Osijek, J. Huttlera 4, 31000 Osijek, Croatia
    • ,
  • Ksenija Marjanovic

      Affiliations

    • Medical School Osijek, University J.J. Strossmayer, J. Huttlera 4, 31000 Osijek, Croatia
    • Department of Pathology, University Hospital Osijek, J. Huttlera 4, 31000 Osijek, Croatia
    • ,
  • Ljubica Glavas-Obrovac

      Affiliations

    • Medical School Osijek, University J.J. Strossmayer, J. Huttlera 4, 31000 Osijek, Croatia

,Accepted 22 March 2009.

References 

  1. Piccioli A, Lensing AW, Prins MH, Falanga A, Scannapieco GL, Ieran M, et al. SOMIT investigators group. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost. 2004;2:884–889
  2. Sallah S, Wan JY. Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients. Cancer. 2001;91:1067–1074
  3. Monreal M, Trujillo-Santos J. Screening for occult cancer in patients with acute venous thromboembolism. Curr Opin Pulm Med. 2007;13:368–371
  4. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of anticoagulation trial. N Engl J Med. 2000;342:1953–1958
  5. Harvey SR, Hurd TC, Markus G, Martinick MI, Penetrante RM, Tan D, et al. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. Clin Cancer Res. 2003;9:4935–4943
  6. Nisato RE, Hosseini G, Sirrenberg C, Butler GS, Crabbe T, Docherty AJ, et al. Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)beta3 in angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-type 1-MMP and alpha(v)beta3 are critical. Cancer Res. 2005;65:9377–9387
  7. Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P, et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 2005;65:3193–3199
  8. Dvorak HF. Rous-Whipple award lecture. How tumors make bad blood vessels and stroma. Am J Pathol. 2003;162:1747–1757
  9. Verheul HM, Hoekman K, Lupu F, Broxterman HJ, van der Valk P, Kakkar AK, et al. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res. 2000;6:166–171
  10. Kuenen BC, Levi M, Meijers JC, Kakkar AK, van Hinsbergh VW, Kostense PJ, et al. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol. 2002;22:1500–1505
  11. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol. 2003;163:1801–1815
  12. Iwata T, Nishiyama N, Nagano K, Izumi N, Mizuguchi S, Morita R, et al. Pulmonary resection for non-small cell lung cancer in patients with hepatocellular carcinoma. World J Surg. 2008;32:2204–2212
  13. Jia YH, Dong XS, Wang XS. Effects of endostatin on expression of vascular endothelial growth factor and its receptors and neovascularization in colonic carcinoma implanted in nude mice. World J Gastroenterol. 2004;10:3361–3364
  14. Sund M, Hamano Y, Sugimoto H, Sudhakar A, Soubasakos M, Yerramalla U, et al. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci USA. 2005;102:2934–2939
  15. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, et al. Antiangiogenic and antitumor effects of bevacizumab in inflammatory and locally advanced breast cancer patients. J Clin Oncol. 2006;24:769–777
  16. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–2019
  17. Johnson DH, Kabbinavar F, Fehrenbacher L, Herbst RS, Nemunaitis JJ, Jablons DM, et al. A phase II, randomized trial comparing bevacizumab (AvastinTM) plus carboplatin/paclitaxel with carboplatin/paclitaxel alone in patients with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer. J Clin Oncol. 2004;22:2184–2191
  18. Heath EI, Burtness BA, Kleinberg L, Salem RR, Yang SC, Heitmiller RF, et al. Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Invest New Drugs. 2006;24:135–140
  19. Behrendt CE, Ruiz RB. Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy. Thromb Haemost. 2003;90:734–737
  20. Huang SF, Kim SJ, Lee AT, Karashima T, Bucana C, Kedar D, et al. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel. Cancer Res. 2002;62:5720–5726
  21. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001;61:3369–3372
  22. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med. 1996;2:209–215
  23. Wojtukiewicz MZ, Sierko E, Zacharski LR, Zimnoch L, Kudryk B, Kisiel W. Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer. Semin Thromb Hemost. 2003;29:291–300
  24. Zanetta L, Marcus SG, Vasile J, Dobryansky M, Cohen H, Eng K, et al. Expression of Von Willebrand factor, an endothelial cell marker, is up-regulated by angiogenesis factors: a potential method for objective assessment of tumor angiogenesis. Int J Cancer. 2000;85:281–288
  25. Damin DC, Rosito MA, Gus P, Roisemberg I, Bandinelli E, Schwartsmann G. Von Willebrand factor in colorectal cancer. Int J Colorectal Dis. 2002;17:42–45
  26. Eppert K, Wunder JS, Aneliunas V, Kandel R, Andrulis IL. von Willebrand factor expression in osteosarcoma metastasis. Mod Pathol. 2005;18:388–397
  27. Mannucci PM, Karimi M, Mosalaei A, Canciani MT, Peyvandi F. Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). Haematologica. 2003;88:454–458
  28. Chiarugi V, Ruggiero M, Magnelli L. Molecular polarity in endothelial cells and tumor-induced angiogenesis. Oncol Res. 2000;12:1–4
  29. Nakashima J, Tachibana M, Ueno M, Baba S, Tazaki H. Tumor necrosis factor and coagulopathy in patients with prostate cancer. Cancer Res. 1995;55:4881–4885
  30. Kim HK, Song KS, Lee KR, Kang YH, Lee YJ, Lee ES. Comparison of plasma D-dimer and thrombus precursor protein in patients with operable breast cancer as a potential predictor of lymph node metastasis. Blood Coagul Fibrinolysis. 2004;15:9–13
  31. Nijziel MR, van Oerle R, Christella M, Thomassen LG, van Pampus EC, Hamulyak K, et al. Acquired resistance to activated protein C in breast cancer patients. Br J Haematol. 2003;120:117–122
  32. Oya M, Akiyama Y, Yanagida T, Akao S, Ishikawa H. Plasma D-dimer level in patients with colorectal cancer: its role as a tumor marker. Surg Today. 1998;28:373–378
  33. Kvolik S, Glavas-Obrovac L, Bares V, Karner I. Effects of inhalation anesthetics halothane, sevoflurane, and isoflurane on human cell lines. Life Sci. 2005;77:2369–2383
  34. Miesbach W, Scharrer I, Asherson R. Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies. Clin Rheumatol. 2006;25:840–844
  35. Chojnowski K, Wawrzyniak E, Trelinski J, Niewiarowska J, Cierniewski C. Assessment of coagulation disorders in patients with acute leukemia before and after cytostatic treatment. Leuk Lymphoma. 1999;36:77–84
  36. Appel IM, Hop WC, van Kessel-Bakvis C, Stigter R, Pieters R. l-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia. Thromb Haemost. 2008;100:330–337
  37. Nijziel MR, van Oerle R, van Pampus EC, de Vet HC, Hillen HF, Hamulyak K. Increased D-dimer levels correlate with binding of activated protein C, but not tissue factor expression, on peripheral blood monocytes in cancer patients. Am J Hematol. 2000;64:282–286
  38. Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis. 2002;13:187–192
  39. Ozturk M, Sengul N, Dagli M, Kosar A, Bavbek N. Global fibrinolytic capacity in colorectal cancer: a new clue to occult fibrinolysis. Clin Appl Thromb Hemost. 2003;9:151–154
  40. Gonzalez-Gronow M, Gawdi G, Pizzo SV. Tissue factor is the receptor for plasminogen type 1 on 1-LN human prostate cancer cells. Blood. 2002;99:4562–4567
  41. Baker EA, Leaper DJ, Hayter JP, Dickenson AJ. Plasminogen activator system in oral squamous cell carcinoma. Br J Oral Maxillofac Surg. 2007;45:623–627
  42. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004;22:1944–1948
  43. Elting LS, Escalante CP, Cooksley C, Avritscher EB, Kurtin D, Hamblin L, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 2004;164:1653–1661
  44. Munter G, Hershko C. Increased warfarin sensitivity as an early manifestation of occult prostate cancer with chronic disseminated intravascular coagulation. Acta Haematol. 2001;105:97–99
  45. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, et al. GIMEMA CMD-working party. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008;93:372–380
  46. Ku GH, White RH, Chew HK, Harvey DJ, Zhou H, Wun T. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood, in press, doi:10.1182/blood-2008-08-175745.
  47. Bergqvist D. Low-molecular-weight heparin for the prevention of postoperative venous thromboembolism after abdominal surgery: a review. Curr Opin Pulm Med. 2005;11:392–397
  48. Scarpa RM, Carrieri G, Gussoni G, Tubaro A, Conti G, Pagliarulo V, et al. Clinically overt venous thromboembolism after urologic cancer surgery: results from the @RISTOS study. Eur Urol. 2007;51:130–135
  49. Boncinelli S, Marsili M, Lorenzi P, Fabbri LP, Pittino S, Filoni M, et al. Haemostatic molecular markers in patients undergoing radical retropubic prostatectomy for prostate cancer and submitted to prophylaxis with unfractioned or low molecular weight heparin. Minerva Anestesiol. 2001;67:693–703
  50. Bernathova M, Jaschke W, Pechlahner C, Zelger B, Bodner G. Primary angiosarcoma of the breast associated Kasabach–Merritt syndrome during pregnancy. Breast. 2006;15:255–258
  51. Angstwurm MW, Dempfle CE, Spannagl M. New disseminated intravascular coagulation score: a useful tool to predict mortality in comparison with acute physiology and chronic health evaluation II and logistic organ dysfunction scores. Crit Care Med. 2006;34:314–320
  52. Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood. 2008;112:250–255
  53. Lee ES, Hibsman BK, Liebman HA. Acquired bleeding disorder in a patient with malignant lymphoma: antibody-mediated prothrombin deficiency. Cancer. 2001;91:636–641
  54. Holm T, Singnomklao T, Rutqvist LE, Cedermark B. Adjuvant preoperative radiotherapy in patients with rectal carcinoma. Adverse effects during long term follow-up of two randomized trials. Cancer. 1996;78:968–976
  55. Mannaerts GH, Van Zundert AA, Meeusen VC, Martijn H, Rutten HJ. Anaesthesia for advanced rectal cancer patients treated with combined major resections and intraoperative radiotherapy. Eur J Anaesthesiol. 2002;19:742–748
  56. Kumar P, Benedict R, Urzua F, Fischbach C, Mooney D, Polverini P. Combination treatment significantly enhances the efficacy of antitumor therapy by preferentially targeting angiogenesis. Lab Invest. 2005;85:756–767
  57. Liu LX, Zhang WH, Jiang HC, Zhu AL, Wu LF, Qi SY, et al. Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer. World J Gastroenterol. 2002;8:663–667
  58. Geh JI, Crellin AM, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg. 2001;88:338–356
  59. Lutgens LC, Deutz NE, Gueulette J, Cleutjens JP, Berger MP, Wouters BG, et al. Citrulline: a physiologic marker enabling quantitation and monitoring of epithelial radiation-induced small bowel damage. Int J Radiat Oncol Biol Phys. 2003;57:1067–1074
  60. Yoshii Y. Pathological review of late cerebral radionecrosis. Brain Tumor Pathol. 2008;25:51–58
  61. Lee JK, Chelvarajah R, King A, David KM. Rare presentations of delayed radiation injury: a lobar hematoma and a cystic space-occupying lesion appearing more than 15 years after cranial radiotherapy: report of two cases. Neurosurgery. 2004;54:1010–1013
  62. Baker PM, Young RH. Radiation-induced pseudocarcinomatous proliferations of the urinary bladder: a report of 4 cases. Hum Pathol. 2000;31:678–683
  63. Zapatero A, Garcia-Vicente F, Modolell I, Alcantara P, Floriano A, Cruz-Conde A, et al. Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose–volume effect. Int J Radiat Oncol Biol Phys. 2004;59:1343–1351
  64. Sarosdy MF. Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy. Cancer. 2004;101:754–760
  65. Isomoto H, Hazama H, Shikuwa S, Omagari K, Mizuta Y, Murase K, et al. A case of haemorrhagic radiation proctitis: successful treatment with argon plasma coagulation. Eur J Gastroenterol Hepatol. 2002;14:901–914
  66. Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004;22:4384–4393
  67. Pectasides D, Tsavdaridis D, Aggouridaki C, Tsavdaridou V, Visvikis A, Tsatalas K, et al. Effects on blood coagulation of adjuvant CNF (cyclophosphamide, novantrone, 5-fluorouracil) chemotherapy in stage II breast cancer patients. Anticancer Res. 1999;19:3521–3526
  68. Kumar A, Chaturvedi P, Gupta YN. Combination chemotherapy for breast carcinoma using a combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) causes a platelet aggregation defect. Int J Cancer. 1996;66:159–161
  69. Strieth S, Nussbaum CF, Eichhorn ME, Fuhrmann M, Teifel M, Michaelis U, et al. Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int J Cancer. 2008;122:452–460
  70. Nuver J, Smit AJ, Sleijfer DT, van Gessel AI, van Roon AM, van der Meer J, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer. 2004;40:701–706
  71. von Tempelhoff GF, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost. 1997;77:456–461
  72. Mitchell LG, Andrew M, Hanna K, Abshire T, Halton J, Wu J, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with l-asparaginase: results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer. 2003;97:508–516
  73. Markman M, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J. Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol. 2004;95:109–113
  74. Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Gaitani S, Visani G, et al. First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. Leuk Res. 2004;28:987–990
  75. Totan M, Dagdemir A, Ak AR, Albayrak D, Kucukoduk S. Effects of high-dose methotrexate on the hemostatic system in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 2001;36:429–433
  76. Fisgin T, Yarali N, Kara A, Bozkurt C, Birgen D, Erten U, et al. Hemostatic side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2004;21:77–83
  77. Morgan M, Dodds A, Atkinson K, Szer J, Downs K, Biggs J. The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Haematol. 1991;77:529–534
  78. Behbakht K, Massad LS, Yordan EL, Lincoln SH, Eriksson JA, Winkelman L, et al. A bleomycin/ifosfamide/cisplatin regimen exhibits poor activity against persistent or recurrent squamous gynecologic cancers. Eur J Gynaecol Oncol. 1996;17:7–12
  79. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev. 2006;(4):CD006019
  80. Lewis KD, Robinson WA, McCarter M, Pearlman N, O'Day SJ, Anderson C, et al. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol. 2006;24:3157–3163
  81. Teymoortash A, Bien S, Dalchow C, Sesterhenn A, Lippert BM, Werner JA. Selective high-dose intra-arterial cisplatin as palliative treatment for incurable head and neck cancer. Onkologie. 2004;27:547–551
  82. Li B, Yu J, Wang L, Li C, Zhou T, Zhai L, et al. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma. Am J Clin Oncol. 2003;26:e92–e99
  83. Engeler DS, Wyler S, Neyer M, Hobi C, Müller J, Schmid HP. Feasibility of early intravesical instillation chemotherapy after transurethral resection of the bladder: a prospective evaluation in a consecutive series of 210 cases. Scand J Urol Nephrol. 2008;42:522–527
  84. Elting LS, Martin CG, Kurtin DJ, Cantor SB, Rubenstein EB, Rodriguez S, et al. The bleeding risk index: a clinical prediction rule to guide the prophylactic use of platelet transfusions in patients with lymphoma or solid tumors. Cancer. 2002;94:3252–3262
  85. Jaime-Perez JC, Cantu-Rodriguez OG, Herrera-Garza JL, Gomez-Almaguer D. Platelet aggregation in children with acute lymphoblastic leukemia during induction of remission therapy. Arch Med Res. 2004;35:141–144
  86. Togna GI, Togna AR, Franconi M, Caprino L. Cisplatin triggers platelet activation. Thromb Res. 2000;99:503–509
  87. Oberhoff C, Szymeczek J, Hoffmann O, Winkler UH, Kaiser S, Schindler AE. Adjuvant antiestrogen treatment with tamoxifen in postmenopausal women with breast cancer: a longitudinal study of blood coagulation and fibrinolysis. Breast Cancer Res Treat. 1998;50:73–81
  88. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, et al. International breast cancer intervention study I investigators. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99:272–282
  89. Oberhoff C, Winkler UH, Hoffmann O, Schindler AE. Adjuvant CMF-chemotherapy and haemostasis. Effect of “classical” and “modified” adjuvant CMF-chemotherapy on blood coagulation fibrinolysis in patients with breast cancer. Eur J Gynaecol Oncol. 2000;21:147–152
  90. Costantino J. The impact of hormonal treatments on quality of life of patients with metastatic breast cancer. Clin Ther. 2002;24:C26–C42
  91. Manso G, Thole Z, Salgueiro E, Revuelta P, Hidalgo A. Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system. Pharmacoepidemiol Drug Saf. 2006;15:253–259
  92. Neudecker J, Junghans T, Ziemer S, Raue W, Schwenk W. Prospective randomized trial to determine the influence of laparoscopic and conventional colorectal resection on intravasal fibrinolytic capacity. Surg Endosc. 2003;17:73–77
  93. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, et al. Surgery for gastric cancer increases plasma levels of vascular endothelial growth factor and von Willebrand factor. Gastric Cancer. 2002;5:137–141
  94. Ayala C, Blackwell KE. Protein C deficiency in microvascular head and neck reconstruction. Laryngoscope. 1999;109:259–265
  95. Yoon YS, Kim SW, Her KH, Park YC, Ahn YJ, Jang JY, et al. Management of postoperative hemorrhage after pancreatoduodenectomy. Hepatogastroenterology. 2003;50:2208–2212
  96. Turrini O, Moutardier V, Guiramand J, Lelong B, Bories E, Sannini A, et al. Hemorrhage after duodenopancreatectomy: impact of neoadjuvant radiochemotherapy and experience with sentinel bleeding. World J Surg. 2005;29:212–216
  97. Gerlach R, Raabe A, Scharrer I, Meixensberger J, Seifert V. Post-operative hematoma after surgery for intracranial meningiomas: causes, avoidable risk factors and clinical outcome. Neurol Res. 2004;26:61–66

PII: S0960-7404(09)00045-0

doi: 10.1016/j.suronc.2009.03.008

Surgical Oncology
Volume 19, Issue 1 , Pages e33-e46 , March 2010

Article Tools

* Image Usage & Resolution